Department of Anesthesiology and Intensive Care, University of Muenster, Muenster, Germany.
Crit Care Med. 2010 Oct;38(10):2016-23. doi: 10.1097/CCM.0b013e3181ef4694.
To compare the effects of a first-line therapy of combined arginine vasopressin, levosimendan, and norepinephrine with arginine vasopressin + norepinephrine or norepinephrine alone in ovine septic shock.
Prospective, randomized, controlled laboratory experiment.
University animal research facility.
Twenty-one chronically instrumented sheep.
After the onset of fecal peritonitis-induced septic shock (mean arterial pressure <60 mm Hg), sheep were randomly assigned to receive first-line treatment with arginine vasopressin (0.5 mU·kg·min), combined arginine vasopressin (0.5 mU·kg·min) and levosimendan (0.2 μg·kg·min), or normal saline (each n = 7) for 24 hrs. In all groups, open-label norepinephrine was additionally titrated to maintain mean arterial pressure at 70 ± 5 mm Hg, if necessary.
Arginine vasopressin + levosimendan + norepinephrine improved left ventricular contractility (higher stroke work indices at similar or lower preload) and pulmonary function (Pao2/Fio2 ratio) when compared with the other groups (p < .05 each). Both nonadrenergic treatment strategies reduced open-label norepinephrine doses. However, only arginine vasopressin + levosimendan + norepinephrine limited fluid requirements and positive fluid balance vs. both other groups (p < .05 each). In addition, arginine vasopressin + levosimendan + norepinephrine increased mixed venous oxygen saturation as compared with arginine vasopressin + norepinephrine. Histologic tissue analyses and pulmonary hemeoxygenase-1 activity revealed no differences among groups. Notably, arginine vasopressin + levosimendan + norepinephrine therapy reduced pulmonary 3-nitrotyrosine levels (p = .028 vs. control animals) as well as urinary protein/creatinine ratio (p < .05 each) and slightly prolonged survival when compared with both other groups (4 hrs vs. arginine vasopressin + norepinephrine: p = .013; 7 hrs vs. norepinephrine alone: p = .003).
First-line cardiovascular support with combined arginine vasopressin and levosimendan supplemented with norepinephrine improves myocardial, vascular, pulmonary, and renal function as compared with arginine vasopressin + norepinephrine in septic shock.
比较一线疗法联合使用血管加压素、左西孟旦和去甲肾上腺素与血管加压素+去甲肾上腺素或单纯去甲肾上腺素治疗绵羊感染性休克的效果。
前瞻性、随机、对照实验室实验。
大学动物研究设施。
21 只慢性仪器化绵羊。
在粪便性腹膜炎引起的感染性休克(平均动脉压<60mmHg)发作后,绵羊被随机分配接受一线治疗,分别接受血管加压素(0.5mU·kg·min)、联合血管加压素(0.5mU·kg·min)和左西孟旦(0.2μg·kg·min)或生理盐水(每组 n=7)治疗 24 小时。在所有组中,如果需要,均另外滴定去甲肾上腺素以维持平均动脉压在 70±5mmHg。
与其他组相比,血管加压素+左西孟旦+去甲肾上腺素可改善左心室收缩力(在相似或更低的前负荷下具有更高的冲程功指数)和肺功能(Pao2/Fio2 比值)(p<0.05 每个)。两种非肾上腺素能治疗策略均减少了去甲肾上腺素的开放标签剂量。然而,只有血管加压素+左西孟旦+去甲肾上腺素与其他两组相比,限制了液体需求并减少了正液体平衡(p<0.05 每个)。此外,与血管加压素+去甲肾上腺素相比,血管加压素+左西孟旦+去甲肾上腺素增加了混合静脉血氧饱和度。组织学分析和肺血红素氧合酶-1 活性在各组之间没有差异。值得注意的是,与其他两组相比,血管加压素+左西孟旦+去甲肾上腺素治疗可降低肺 3-硝基酪氨酸水平(p=0.028 与对照组)以及尿蛋白/肌酐比值(p<0.05 每个),并略微延长了与其他两组相比的存活时间(4 小时与血管加压素+去甲肾上腺素:p=0.013;7 小时与单纯去甲肾上腺素:p=0.003)。
与血管加压素+去甲肾上腺素相比,在感染性休克中,一线心血管支持联合使用血管加压素和左西孟旦,并补充去甲肾上腺素可改善心肌、血管、肺和肾功能。